Bright Rock Capital Management LLC continued to hold its stake in shares of Edwards Lifesciences Corporation (NYSE:EW) during the second quarter, Holdings Channel reports. The institutional investor owned 14,000 shares of the medical research company’s stock at the end of the second quarter. Bright Rock Capital Management LLC’s holdings in Edwards Lifesciences Corporation were worth $1,655,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently made changes to their positions in the stock. Cigna Investments Inc. New purchased a new stake in shares of Edwards Lifesciences Corporation during the second quarter worth about $971,000. Kelly Lawrence W & Associates Inc. CA raised its stake in shares of Edwards Lifesciences Corporation by 1.3% in the second quarter. Kelly Lawrence W & Associates Inc. CA now owns 47,200 shares of the medical research company’s stock worth $5,581,000 after buying an additional 600 shares during the last quarter. Shine Investment Advisory Services Inc. purchased a new stake in shares of Edwards Lifesciences Corporation during the second quarter worth about $126,000. Pioneer Investment Management Inc. raised its stake in shares of Edwards Lifesciences Corporation by 5.8% in the second quarter. Pioneer Investment Management Inc. now owns 684,809 shares of the medical research company’s stock worth $80,971,000 after buying an additional 37,652 shares during the last quarter. Finally, BP PLC raised its stake in shares of Edwards Lifesciences Corporation by 88.0% in the second quarter. BP PLC now owns 47,000 shares of the medical research company’s stock worth $5,558,000 after buying an additional 22,000 shares during the last quarter. 84.15% of the stock is currently owned by institutional investors.

Edwards Lifesciences Corporation (NYSE EW) opened at 116.26 on Thursday. The firm has a 50-day moving average of $117.20 and a 200 day moving average of $105.15. Edwards Lifesciences Corporation has a 1-year low of $81.12 and a 1-year high of $121.75. The firm has a market cap of $24.55 billion, a P/E ratio of 35.26 and a beta of 0.63.

Edwards Lifesciences Corporation (NYSE:EW) last announced its quarterly earnings data on Wednesday, July 26th. The medical research company reported $1.08 earnings per share for the quarter, beating analysts’ consensus estimates of $0.88 by $0.20. Edwards Lifesciences Corporation had a net margin of 22.16% and a return on equity of 27.17%. The business had revenue of $842 million during the quarter, compared to the consensus estimate of $839.16 million. During the same quarter in the prior year, the firm earned $0.76 EPS. The company’s revenue for the quarter was up 10.9% compared to the same quarter last year. On average, analysts predict that Edwards Lifesciences Corporation will post $3.78 EPS for the current year.

ILLEGAL ACTIVITY WARNING: “Bright Rock Capital Management LLC Continues to Hold Position in Edwards Lifesciences Corporation (NYSE:EW)” was first reported by Watch List News and is owned by of Watch List News. If you are reading this news story on another site, it was copied illegally and republished in violation of United States & international copyright and trademark law. The correct version of this news story can be viewed at https://www.watchlistnews.com/bright-rock-capital-management-llc-continues-to-hold-position-in-edwards-lifesciences-corporation-nyseew/1469886.html.

A number of brokerages have issued reports on EW. Canaccord Genuity reissued a “buy” rating and issued a $155.00 target price (up previously from $150.00) on shares of Edwards Lifesciences Corporation in a research report on Sunday, July 30th. Royal Bank Of Canada reissued a “buy” rating and issued a $130.00 target price on shares of Edwards Lifesciences Corporation in a research report on Friday, July 28th. Cowen and Company reissued an “outperform” rating and issued a $135.00 target price (up previously from $130.00) on shares of Edwards Lifesciences Corporation in a research report on Thursday, July 27th. Barclays PLC boosted their target price on Edwards Lifesciences Corporation from $108.00 to $120.00 and gave the company an “equal weight” rating in a research report on Thursday, July 27th. Finally, Stifel Nicolaus reissued a “buy” rating and issued a $130.00 target price (up previously from $118.00) on shares of Edwards Lifesciences Corporation in a research report on Thursday, July 27th. Five research analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has assigned a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus target price of $121.13.

In related news, VP Catherine M. Szyman sold 4,681 shares of the business’s stock in a transaction dated Monday, July 31st. The shares were sold at an average price of $115.78, for a total transaction of $541,966.18. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Michael A. Mussallem sold 32,900 shares of the business’s stock in a transaction dated Wednesday, June 7th. The shares were sold at an average price of $118.05, for a total transaction of $3,883,845.00. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 150,512 shares of company stock valued at $17,360,159. Insiders own 2.13% of the company’s stock.

About Edwards Lifesciences Corporation

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corporation (NYSE:EW).

Institutional Ownership by Quarter for Edwards Lifesciences Corporation (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.